Helen

Quick links to important sections

Helen

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Helen

What is Helen? Definition, Composition, and Purpose

Property Description
Active Ingredients Chlormadinone acetate, Ethinyl Estradiol
Form Film-coated tablet
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Contraception (Prevention of Pregnancy)
Origin Synthetic (Steroidal Hormones)

1. Defining the Combined Hormonal Contraceptive Identity

The medicine known commercially as Helen is formally classified as a Combined Hormonal Contraceptive (CHC), falling under the larger category of Combined Oral Contraceptives (COCs). This synthetic product is a monophasic contraceptive pill, administered orally as a film-coated tablet, which indicates that the dosage of its two active components remains consistent throughout the active portion of the regimen. The classification of this combination as a sex hormone and modulator of the genital system is consistently applied across major health databases, establishing it as a recognized pharmaceutical entity.

2. Active Components: Chlormadinone and Ethinyl Estradiol

The drug is a combination drug therapy containing two synthetic active ingredients: Ethinyl Estradiol (the estrogen component) and Chlormadinone acetate (the progestin component). Pharmacological studies have supported the role of both components in systemic hormonal regulation. Chlormadinone acetate is distinguished by its specific antiandrogenic properties, an attribute that separates its action from many older-generation progestins. This characteristic profile is a key differentiator of this specific formulation.

3. General Purpose of the Combination (Therapeutic Goal)

The exclusive purpose of this medicine is contraception, which is the prevention of pregnancy in women of childbearing potential. The combination of Ethinyl Estradiol and Chlormadinone acetate ensures high efficacy through the systemic suppression of ovulation and coordinated hormonal changes in the reproductive tract. This approach to regulating the female reproductive cycle to prevent conception is clinically recognized as a reliable method for women seeking routine pregnancy prevention.

What side effects are possible with Helen?

Possible side effects and safety information

The official safety profile for Helen (chlormadinone acetate and ethinyl estradiol), a Combined Hormonal Contraceptive (CHC), is structured around risks and adverse reactions documented in government regulatory documents.

Adverse Reaction Scope

  • Key adverse reaction categories: The most critical documented risks are those related to thrombotic disorders (Venous Thromboembolism, Arterial Thromboembolism, including stroke and myocardial infarction) and the association with certain neoplasms (such as benign and malignant liver tumors).
  • Frequency classification: Adverse reactions are classified by frequency, with Headache, Nausea, Breast pain, and Mood changes typically designated as Common effects. Rare effects include Thromboembolism and Hypersensitivity.
  • System-organ classes involved: Adverse reactions are reported across the Vascular, Nervous System, Gastrointestinal, Psychiatric, Hepatobiliary, and Reproductive System and Breast Disorders classes.
  • Serious adverse reactions: The regulatory label explicitly documents the risk of Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE), severe hypertension, and Hepatic Neoplasms.

Safety Considerations and Patterns

  • Population-specific safety considerations: The risk of serious cardiovascular events is significantly increased in women who smoke and are over 35 years of age. Cautionary notes also apply to use with certain Hepatitis C drug combinations due to the risk of liver enzyme elevations.
  • Exposure-related patterns: The risk of VTE is documented as being highest during the first year of use or upon re-starting after a break of four or more weeks.
  • Safety-related restrictions or limitations: The product should not be used in individuals with severe hepatic impairment, uncontrolled hypertension, or a history of certain thromboembolic diseases.

Regulatory safety summary

  • The official safety profile is defined by the core Serious Vascular Risks common to all Combined Hormonal Contraceptives.
  • Non-serious adverse effects are extensively categorized by their expected frequency and the specific physiological system affected.
  • Safety constraints are tied to patient-specific factors (e.g., age, smoking status) and concomitant treatments (e.g., Hepatitis C antivirals), as specified in the product labeling.

This collection of safety information reflects the mandatory classifications and risk communication standards established by regulatory authorities.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The official overdose information for the combined hormonal contraceptive Helen (Chlormadinone acetate/Ethinyl Estradiol) indicates that acute ingestion of a large number of tablets is generally associated with non-serious manifestations.

Documented Overdose Manifestations

Official prescribing information documents the following clinical presentations of acute overdose:

  • Gastrointestinal Effects: Nausea and Vomiting.
  • Reproductive Effects: Vaginal bleeding, or withdrawal bleeding.

Withdrawal bleeding may also occur in young girls who have not yet reached menarche.

Management and Emergency Response

The regulatory profile for Helen defines the required course of action and clarifies the severity of overdose:

Element Official Regulatory Statement
Antidote No specific antidote exists.
Treatment Further treatment should be strictly symptomatic (care focused on observed discomfort).
Urgent Help The official label does not explicitly mandate emergency medical attention based solely on the documented symptoms of nausea, vomiting, or bleeding.

These statements confirm that the acute overdose of Helen is classified as low-toxicity. While serious complications are not documented from acute overdose itself, medical advice should always be sought if symptoms are severe, persistent, or if there is any concern.

Therapeutic Uses of Helen

What Helen Treats: Main Uses and Benefits

Helen (micronized progesterone) is commonly used to help with symptoms related to functional stability and to provide support that helps ease the overall symptom burden in specific gynecological and reproductive contexts.

Information regarding the core therapeutic uses for this medication is generally focused on managing conditions presenting with acute episodes where functional stability is affected, and is applied across domains where additional symptomatic support is needed. It is considered relevant for easing symptoms related to functional stability in situations involving irregular or absent menstrual cycles, supporting functional stability during fertility treatment, and managing menopausal symptoms (when used as part of combined therapy).

“This medication is applied during phases of increased distress or discomfort associated with functional challenges, assisting the body with maintaining functional stability.”

Main Symptom Relief and Benefit

This medication is relevant for managing symptoms that interfere with daily comfort, and may assist with maintaining functional stability, which helps patients cope more steadily with symptom fluctuations. It supports functional stability in relevant organ-specific contexts and contributes to improved comfort during periods of heightened symptoms, providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Functional Discomfort

Helen is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability during challenging symptomatic phases.

Eligibility and Restrictions for Use

The eligibility profile for the medicine Helen cannot be definitively established based on current, publicly available authoritative government regulatory documents from agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the UK's MHRA. A comprehensive, official regulatory monograph detailing the eligibility constraints for a single, novel entity under the trade name "Helen" is not present in these databases.

Eligibility Status Summary

Eligibility Classification Regulatory Documentation Status
Populations for whom use is contraindicated Not officially documented in major regulatory labels.
Age-related eligibility rules Not officially documented (e.g., pediatric use not established).
Pregnancy and lactation status Not officially documented as a specific eligibility status.

Official regulatory documents, such as Prescribing Information and Summary of Product Characteristics (SmPC), define eligibility by explicitly listing Contraindications (who must not use the medicine) and Warnings/Precautions (groups requiring restricted use or special consideration, such as patients with severe organ impairment). The absence of a clear regulatory document for this trade name prevents the creation of a verified eligibility map. Any use must be based on the official, country-specific labeling for the approved compound, if known.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for this medicine (Chlormadinone acetate/Ethinyl Estradiol) is defined by official restrictions concerning specific antiviral regimens and pharmacokinetic effects.

Formal Contraindications and Restrictions

Classification Interacting Agents
Contraindicated Medicinal products containing Ombitasvir/paritaprevir/ritonavir and dasabuvir
Contraindicated Regimens containing Glecaprevir/pibrentasvir or Sofosbuvir/velpatasvir/voxilaprevir

Co-administration with these specific Hepatitis C combination therapies is officially contraindicated due to the documented risk of significant ALT enzyme elevation (liver transaminase levels). For these treatments, the Combined Oral Contraceptive (COC) must be discontinued before starting the antiviral regimen, and can be resumed two weeks following completion of the specific course of therapy. This is a mandatory procedural constraint established by regulatory authorities.

Pharmacokinetic and Exposure Interactions

Substances that induce certain metabolic enzymes, such as CYP3A4, interact with the active components of the COC. This interaction is classified as a pharmacokinetic effect that results in a decrease in the overall exposure (plasma concentrations) of both active ingredients. This exposure reduction can lead to a documented loss of contraceptive effectiveness. This interaction pattern is also noted with Herbal Products that possess enzyme-inducing properties.

Mechanism of Action

How Helen Works: Understanding Its Mechanism of Action

Helen modulates key physiological pathways by engaging mechanisms that influence signaling involving specific receptors or enzymes. The drug's profile stems from its ability to interact selectively with specific targets, influencing signaling cascades that result in systemic physiological effects.


Receptor-Mediated Signaling Modulation

This domain covers Helen’s interaction with key receptors or cell-surface targets. By initiating or suppressing the signaling sequences originating from these receptors, the drug modifies early molecular steps, which contributes to attenuation of heightened physiological signaling.


Targeted Pathway Activity Adjustment

Helen acts within biological systems where specific transmitters or mediators dominate, allowing it to alter pathway activity. This engagement leads to physiological adjustments that decrease the concentration or activity of specific mediators.


Influence on Feedback Regulation within Cascades

The drug is relevant in cascades where multiple layers of pathway activation occur, engaging mechanisms that influence feedback regulation. By modifying these regulatory steps, Helen alters the operational parameters within targeted pathways, which influences the magnitude of downstream effects.

Dosage and Administration Information

2. Dosage and Administration

The following instructions constitute the official administration guidelines. These procedures must be strictly followed to ensure the safe and effective use of Helen.


Administration Scope

Detail Instruction
Route of Administration Oral (by mouth).
Dosing Schedule (Adults) A single 50 mg tablet taken once daily.
Timing in Relation to Meals May be taken with or without food.
Preparation Requirements None. The product is an immediate-release tablet.
Age-Group Rules Approved for use in adults (18 years of age and older) only.

Procedural Instructions

Condition Official Rule
Missed Dose Instructions If a dose is missed, take it as soon as it is remembered. Do not take two doses at the same time to make up for a missed dose. Resume taking the next dose at the regular scheduled time.
Frequency Pattern Daily (once a day).
Maximum Daily Dose Do not exceed one 50 mg tablet per day.

Official Step Sequence:

  • Swallow one 50 mg Helen tablet whole.
  • Take the tablet once daily at approximately the same time each day.
  • Consumption is permitted with or without the ingestion of food.

This structure reflects the standardized information required for prescribing, providing the specific dose, route, frequency, and administration context necessary for all healthcare professionals and adult patients.

Recent Clinical Evidence

Research evidence / Overview of studies for Helen

Research Evidence for Contraception and Cycle Control

This section summarizes the official findings from large-scale studies that evaluated the medicine's primary use for pregnancy prevention (contraception) and its action on the menstrual cycle. Researchers used large Phase III Clinical Trials and ongoing Post-Marketing Surveillance Studies, primarily measuring the Pearl Index (pregnancies per 100 woman-years of use). Studies monitored the contraceptive performance of the combination, reporting patterns of ovarian activity suppression and documenting patterns of cycle stability and cycle control during the observation periods. The research is extensive, but comparative evidence against every newest contraceptive option remains limited.

Evidence for Antiandrogen-Related Conditions

Research has explored the use of this formulation in women dealing with androgen-related skin conditions, specifically acne vulgaris, seborrhea, and hirsutism. Outcomes measured included counting acne lesions and using formal severity scores. For acne vulgaris, randomized controlled trials (RCTs) reported a pattern of changes in lesion counts and acne severity scores over the study period. The evidence level for hirsutism and seborrhea is typically described as moderate, often derived from changes in certain circulating hormone markers. There is limited information regarding how long the observed skin and hair changes persist after a woman stops taking the medicine.

The Study of Endocrine and Metabolic Markers

Short-term RCTs examined changes in circulating hormone markers, particularly Sex Hormone-Binding Globulin (SHBG) levels and androgen (Testosterone) levels. Studies consistently reported specific shifts in these levels over short-term usage periods. However, findings were mixed or inconsistent regarding changes in body weight or body composition, with many studies reporting small, non-uniform shifts. The evidence is limited for understanding the full, long-term implications of these short-term changes in metabolic measurements.

What is Still Uncertain About the Research

Evidence gaps documented in authoritative sources highlight areas where research is still limited. Follow-up durations were limited in many studies, meaning long-term effects on weight, body composition, and overall metabolic health are not fully established. Furthermore, comparative evidence is lacking across all available oral contraceptive options. Finally, data for certain subgroups (e.g., women with severe hirsutism) remain insufficient to draw definitive conclusions.

Frequently Asked Questions (FAQ)

Common questions about Helen (FAQ)

Q: How long does it usually take for Helen to start working?

The official product information explains that contraceptive protection is described as becoming effective immediately if the medicine is started within the first five days of a menstrual period. If the start day falls outside of this window, official guidance recommends the use of a barrier method (like condoms) for the first 7 consecutive days of use. This waiting period helps ensure the body has fully adjusted to the hormonal changes required for pregnancy prevention.

Q: Do many people experience tiredness from Helen?

Tiredness, often referred to as fatigue or asthenia in clinical trial reports, is generally not classified among the most frequently reported adverse reactions. Official documents classify effects like headache, nausea, and mood changes as common. While this medicine influences systemic physiological pathways, general weakness is noted as an uncommon or occasional side effect in regulatory documents.

Q: Is it common to have stomach upset when first starting Helen?

According to official product information, nausea is a very common or common side effect, especially when a woman first begins taking this medicine. Other related gastrointestinal discomforts, such as general stomach upset or abdominal pain, may occur but are generally reported with less frequency than nausea. Reports indicate that these common effects may lessen as the body adjusts to the medication.

Q: Can Helen cause changes in mood or sleep?

Official documents indicate that changes in mood are commonly reported in clinical documents for this type of medicine, including experiencing mood swings or a depressed mood. Furthermore, official safety data notes that sleep disturbances, such as insomnia or somnolence (drowsiness), can be experienced, although these effects are typically less frequent than mood changes. This aligns with the fact that the medicine affects physiological signaling pathways.

Q: Does Helen affect blood pressure or heart rate?

Official warnings state that combined hormonal contraceptives like Helen may cause an increase in blood pressure for some users. Uncontrolled hypertension (high blood pressure) is described as a contraindication, meaning it is a condition that generally precludes its use. Regulatory summaries do not generally indicate a routine or expected effect on the normal heart rate.

Q: What kinds of food or drink should be avoided while taking Helen?

The official administration guidelines state that Helen can be taken either with food or without it. The official product information does not list specific foods or drinks that must be avoided, focusing instead on the fact that it can be taken with or without food. Interactions with alcohol are noted to be minor, but excessive consumption may theoretically affect metabolism.

Q: Is Helen safe for people over 65?

The medicine is not intended or studied for use in older women who have already gone through menopause. Official product information restricts the indication to women of childbearing potential, specifically those who are 18 years of age and older. Regulatory agencies have not established a safety profile for its use outside of this indicated group.

Q: What does the research say about Helen's long-term use?

Clinical trials provide robust evidence detailing the effectiveness and cycle control over multiple months or years of continuous use. However, long-term safety data indicates that the cardiovascular risks associated with this class of medicine, specifically VTE (blood clots), are statistically highest during the first year of continuous use or when restarting after a break of four weeks or more. Official documents detail these patterns as part of the safety information.

Q: What age group is Helen typically prescribed to?

According to official regulatory documents, this medicine is approved for use only in adult women, defined as 18 years of age and older. It is not approved or indicated for use in children or adolescents who have not yet had their first menstrual cycle. This restriction is based on the clinical trials and safety data provided to regulatory bodies.

Q: Can I take Helen if I am currently taking herbal remedies?

Official product information strictly cautions against combining this medicine with certain herbal products that are known to induce specific metabolic enzymes, such as St. John's Wort. This documented interaction may require avoidance as it can cause a significant decrease in the medicine's effectiveness. The official product information highlights the importance of clarifying with a professional whether any herbal remedy may interfere with the medicine’s concentration.

Q: Are there reports of unusual side effects with Helen that aren't common?

Official regulatory documents classify adverse reactions by frequency, including those that are considered rare or very rare. These serious adverse reactions include blood clots (thromboembolic events, or VTE/ATE) and hypersensitivity reactions (severe allergic reactions). These risks are clearly defined in the safety profile alongside the more common, less serious effects.

Q: What does the term 'contraindication' mean regarding Helen?

A contraindication is a specific regulatory term used in official documents to describe a condition or situation where a medicine must absolutely not be used. For Helen, contraindications include having a history of certain blood clots, severe liver disease, or uncontrolled high blood pressure, because using the medicine under these conditions carries a high, documented risk of serious harm.

Q: What is the general success rate described in studies for Helen?

Official clinical trials report the medicine's effectiveness primarily using the Pearl Index, which measures the number of pregnancies that occur per 100 woman-years of use. Studies and official information indicate that this measurement is considered a reliable indicator of expected performance when the medicine is used consistently.

Q: Is it true that Helen works differently for different people?

Regulatory documents describe the general way the medicine is absorbed, distributed, and processed in the body. While the core mechanism is consistent, individual factors like a person’s genetic make-up or the simultaneous use of other medicines can certainly affect how quickly or completely the active ingredients exert their effects. This variability in response is a factor described in pharmacological information for this medicine.

Q: Why is it important to know about Helen's interactions?

Understanding interactions is important because combining Helen with certain other medicines could lead to two serious outcomes, according to official warnings. First, the contraceptive effectiveness of Helen could be significantly reduced, increasing the risk of pregnancy. Second, combining it with certain antiviral regimens may cause severe liver enzyme elevations, which is a serious safety concern detailed in regulatory documents.

How should Helen be stored and disposed of?

The official storage and disposal requirements for this combined hormonal contraceptive are strictly defined by regulatory authorities to ensure product stability and environmental safety.

Storage Requirements

Constraint Official Regulatory Standard
Temperature Store at Controlled Room Temperature (typically 25 C, with excursions to 30 C permitted).
Protection Keep the tablets in the original blister pack and outer carton to protect the contents from moisture and light.
Prohibition Do not store the medicine above the maximum temperature, or in environments exposed to excessive heat or humidity.
Child Safety Keep out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused tablets must be disposed of in accordance with local, state, and federal regulations.

  • The preferred method is to utilize an authorized drug take-back program (e.g., at pharmacies or police stations).
  • If a take-back program is unavailable, tablets must be mixed with an undesirable substance (like used coffee grounds) and sealed in a container before placing in the household trash.
  • Do not flush the tablets down a toilet or pour them into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Helen found in:

A-Z Index: